- Home
- RQI vs VIR Comparison
RQI vs VIR Comparison
Compare RQI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RQI | VIR |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RQI | VIR |
|---|---|---|
| Price | $11.31 | $10.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 774.2K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 8.20% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | N/A | $257.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.81 | $4.82 |
| 52 Week High | $13.57 | $12.00 |
Technical Indicators
Market Signals| Indicator | RQI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 47.63 |
| Support Level | $10.84 | $10.00 |
| Resistance Level | $11.32 | $11.83 |
| Average True Range (ATR) | 0.20 | 0.62 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 74.91 | 30.62 |
Price Performance
Historical ComparisonAbout RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. The Fund's secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.